Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)

References

• Beckmann K, Garmo H, Adolfsson J, et al. Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. Eur Urol. 2019;75(4):676–683.
   PubMed Web of Science ®Google Scholar
• Thomsen FB, Bosco C, Garmo H, et al. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncol. 2019;58(1):110–118.
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447–456.
   PubMed Web of Science ®Google Scholar
• Iversen P, McLeod DG, See WA, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105(8):1074–1081.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505.
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–282.
   Web of Science ®Google Scholar
• Virgo KS, Rumble RB, de Wit R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39(11):1274–1305.
   PubMed Web of Science ®Google Scholar
• Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–987.
   PubMed Web of Science ®Google Scholar
• Pinover WH, Horwitz EM, Hanlon AL, et al. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer. 2003;97(4):1127–1133.
   PubMed Web of Science ®Google Scholar
• Klayton TL, Ruth K, Buyyounouski MK, et al. PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT Or IMRT using the phoenix definition. Pract Radiat Oncol. 2011;1(4):235–242.
   PubMedGoogle Scholar
• van den Bergh RC, van Casteren NJ, van den Broeck T, et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence After local curative treatment: a systematic review. Eur Urol. 2016;69(5):802–820.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• Oudard S, Latorzeff I, Caty A, et al. Effect of adding docetaxel to androgen-deprivation therapy in patients with high-risk prostate cancer with rising prostate-specific antigen levels after primary local therapy: a randomized clinical trial. JAMA Oncol. 2019;5(5):623–632.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Mota JM, Lacuna K, et al. Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503). Eur Urol Oncol. 2021;4(4):543–552.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–308.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Bianco F, Dahut WL, et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol. 2008;179(6):2181–2185. discussion 2185–2186.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Ylitalo EB, Thysell E, Thellenberg-Karlsson C, et al. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens. Prostate. 2020;80(2):214–224.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu C, Armstrong C, et al. Antiandrogens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer. Clin Cancer Res. 2015;21(18):4133–4142.
   PubMed Web of Science ®Google Scholar
• Lombard AP, Liu C, Armstrong CM, et al. ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol Cancer Ther. 2017;16(10):2257–2266.
   PubMed Web of Science ®Google Scholar
• Mout L, van Royen ME, de Ridder C, et al. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine. 2021;73:103681.
   PubMed Web of Science ®Google Scholar
• Mang J, Merkle K, Heller M, et al. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells. Urol Oncol. 2017;35(1):32.e39–32.e16.
   Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803.
   PubMed Web of Science ®Google Scholar
• Ahlgren GM, Flodgren P, Tammela TLJ, et al. Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 scandinavian prostate cancer group 12 trial. Eur Urol. 2018;73(6):870–876.
   PubMed Web of Science ®Google Scholar
• Lin DW, Shih MC, Aronson W, et al. Veterans affairs cooperative studies program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study. Eur Urol. 2020;77(5):563–572.
   PubMed Web of Science ®Google Scholar
• Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, et al. Docetaxel versus surveillance after radical radiotherapy for intermediate- or high-risk prostate cancer-results from the prospective, randomised, open-label phase III SPCG-13 trial. Eur Urol. 2019;76(6):823–830.
   PubMed Web of Science ®Google Scholar
• Tannock IF. The five rs of chemotherapy. Lancet Oncol. 2016;17(6):703–705.
   PubMed Web of Science ®Google Scholar
• Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189–3197.
   PubMed Web of Science ®Google Scholar
• Maeda H, Takeda K, Urushihara H, et al. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Cancer Rep. 2021;4(3):e1334.
   Google Scholar
• Xie W, Regan MM, Buyse M, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097–3104.
   PubMed Web of Science ®Google Scholar
• Caglar M, Tuncel M, Yildiz E, et al. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with ga-68 PSMA PET/CT. Ann Nucl Med. 2020;34(12):932–941.
   PubMed Web of Science ®Google Scholar
• Crocerossa F, Marchioni M, Novara G, et al. Detection rate of prostate-specific membrane antigen tracers for positron emission tomography/computed tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis. J Urol. 2021;205:356–369.
   Google Scholar